Component
One-third distal radius bone mineral density
One-third distal radius bone mineral density. Species, exposure and limitations are retained in each linked claim.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
MK-7 produced greater one-third distal-radius BMD loss than placebo: change difference -0.023 g/cm2, 95% CI -0.039 to -0.008.
Experimental context and source evidence
- evidence_span
- {"source_cache": "artifacts/k2-research/36460034.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "7a8ad2542116a1ddc804eead1694c7057dfaff243eacb993c6c39745e73264a0", "start_char": 0, "end_char": 1754, "text_sha256": "7a8ad2542116a1ddc804eead1694c7057dfaff243eacb993c6c39745e73264a0"}
- experimental_model
- Two-year randomized double-blind RenaKvit trial
- exposure
- MK-7 360 micrograms/day versus placebo
- limitations
- Kidney-disease context and substantial attrition; site-specific findings cannot be condensed into universal bone benefit or harm.
- nutrient_topic
- Vitamin K2 research collection; topical membership is not evidence of a direct dietary effect. · Vitamin K2 / menaquinone family
- organism
- 123 chronic-dialysis patients randomized
- plain_language
- One skeletal site had a worse result despite improved vitamin K markers.
- primary_references
- [k2-p36460034] Vitamin K supplementation and bone mineral density in dialysis: results of the double-blind, randomized, placebo-controlled RenaKvit trial. (2023). https://pubmed.ncbi.nlm.nih.gov/36460034/ DOI: 10.1093/ndt/gfac315
- tissue_or_cell_type
- Site-specific BMD
Vitamin K2: menaquinone forms, carboxylation, recycling and nutrient interactions (2026-09-17) · lines 1124–1135
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Two-year randomized double-blind RenaKvit trial · source_derived_draft · unverified_draft
### k2-dialysis-radius MK-7 produced greater one-third distal-radius BMD loss than placebo: change difference -0.023 g/cm2, 95% CI -0.039 to -0.008. Condition category: normal nutrient_topic: Vitamin K2 research collection; topical membership is not evidence of a direct dietary effect. plain_language: One skeletal site had a worse result despite improved vitamin K markers. organism: 123 chronic-dialysis patients randomized tissue_or_cell_type: Site-specific BMD experimental_model: Two-year randomized double-blind RenaKvit trial limitations: Kidney-disease context and substantial attrition; site-specific findings cannot be condensed into universal bone benefit or harm. exposure: MK-7 360 micrograms/day versus placebo evidence_span: {"source_cache": "artifacts/k2-research/36460034.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "7a8ad2542116a1ddc804eead1694c7057dfaff243eacb993c6c39745e73264a0", "start_char": 0, "end_char": 1754, "text_sha256": "7a8ad2542116a1ddc804eead1694c7057dfaff243eacb993c6c39745e73264a0"} [k2-p36460034] Vitamin K supplementation and bone mineral density in dialysis: results of the double-blind, randomized, placebo-controlled RenaKvit trial. (2023). https://pubmed.ncbi.nlm.nih.gov/36460034/ DOI: 10.1093/ndt/gfac315
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.